Alto Neuroscience
NYSE: ANROMountain View, US · Founded 2019 · Delaware corporation · 8 known investors
Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates. Its initial focus areas include major depressive disorder, bipolar depression, and schizophrenia.
BiotechDigital HealthMental Health
Founders & leadership
Alto Neuroscience was founded in 2019 by Amit Etkin.
AE
Amit EtkinFounder
AS
Adam SavitzExecutive
NC
Nicholas C. SmithExecutive
MH
Michael HanleyExecutive
AW
Aaron WeaverNamed on SEC filing
PY
Po Yu (Jeff) ChenNamed on SEC filing
CD
Chris DimitropoulosNamed on SEC filing
Board
GY
Gwill YorkBoard director
CN
ML
HM
Husseini ManjiBoard director
RS
Raymond SanchezBoard director
Investors · 8
Reported raises · per SEC filings
Form D private placements$193.9M disclosed across 5 of 6 rounds · 2019–2026
▶$50MraisedOct 2025 · 7 investors · PharmaceuticalsRule 506(b)
▶$50MraisedOct 2025 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Adam SavitzExecutive Officer
- Amit EtkinExecutive Officer, Director
- Nicholas C. SmithExecutive Officer
- Gwill YorkDirector
- Husseini ManjiDirector
- Christopher Nixon CoxDirector
- Raymond SanchezDirector
- Andrew DreyfusDirector
- Michael HanleyExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45MraisedNov 2023 · 16 investors · BiotechnologyRule 506(b)
▶$45MraisedNov 2023 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael LiangDirector
- Adam SavitzExecutive Officer
- Christopher Nixon CoxDirector
- Po Yu (Jeff) ChenDirector
- Andrew DreyfusDirector
- Amit EtkinExecutive Officer, Director
- Aaron WeaverDirector
- Chris DimitropoulosDirector
- Nicholas SmithExecutive Officer
- Gwill YorkDirector
- Offering amount
- $45M
- Amount sold
- $45M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$31.9MraisedNov 2023 · 19 investors · BiotechnologyRule 506(b)
▶$31.9MraisedNov 2023 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew DreyfusDirector
- Michael LiangDirector
- Aaron WeaverDirector
- Christopher Nixon CoxDirector
- Adam SavitzExecutive Officer
- Nicholas SmithExecutive Officer
- Gwill YorkDirector
- Po Yu (Jeff) ChenDirector
- Chris DimitropoulosDirector
- Amit EtkinExecutive Officer, Director
- Offering amount
- $31.9M
- Amount sold
- $31.9M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$59.3MraisedNov 2023 · 26 investors · BiotechnologyRule 506(b)
▶$59.3MraisedNov 2023 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Po Yu (Jeff) ChenDirector
- Aaron WeaverDirector
- Gwill YorkDirector
- Amit EtkinExecutive Officer, Director
- Chris DimitropoulosDirector
- Michael LiangDirector
- Adam SavitzExecutive Officer
- Christopher Nixon CoxDirector
- Andrew DreyfusDirector
- Nicholas SmithExecutive Officer
- Offering amount
- $59.3M
- Amount sold
- $59.3M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$7.7MraisedNov 2023 · 16 investors · BiotechnologyRule 506(b)
▶$7.7MraisedNov 2023 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chris DimitropoulosDirector
- Christopher Nixon CoxDirector
- Michael LiangDirector
- Aaron WeaverDirector
- Andrew DreyfusDirector
- Nicholas SmithExecutive Officer
- Gwill YorkDirector
- Adam SavitzExecutive Officer
- Po Yu (Jeff) ChenDirector
- Amit EtkinExecutive Officer, Director
- Offering amount
- $7.7M
- Amount sold
- $7.7M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapAltos Labs19 shared keywordsAltos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.
Bioworld15 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Alto Neuroscience for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3.2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?finance.yahoo.com · Aug 2026Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plansfinance.yahoo.com · Aug 2026Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?finance.yahoo.com · Aug 2026
Alto Neuroscience grows cash reserves but widens loss | ANRO Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Alto Neuroscience do?
- Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates. Its initial focus areas include major depressive disorder, bipolar depression, and schizophrenia.
- Who founded Alto Neuroscience?
- Alto Neuroscience was founded by Amit Etkin in 2019.
- Who are Alto Neuroscience's investors?
- Alto Neuroscience's investors include Able Partners, Alpha Wave Global, InVivium Capital, K2 HealthVentures, Korify Capital, Vivo Capital, What If Ventures, Windham Capital Partners.
- How much funding has Alto Neuroscience raised?
- Alto Neuroscience has disclosed $193.9M raised across 5 of its 6 known rounds.
- Where is Alto Neuroscience headquartered?
- Alto Neuroscience is headquartered in Mountain View, US.